Citations

Showing 10 of 108094 citations.

Robotic-assisted Bronchoscopy to Diagnose Malakoplakia
Sakata, Kenneth K. , Azadeh, Natalya , Kim, Jeeho , Smith, Maxwell L.

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | August 2, 2022 | Volume: 30 | Issue: 2 | Pages: 174-176

10.1097/lbr.0000000000000861 | PMID 35916425 Get It

Surgical Management of Aortic Regurgitation in Takayasu’s Arteritis: A Systematic Review of Techniques and Outcomes
Fath, Ayman R , Mookadam, Farouk, Aglan, Amro , Eldaly, Abdullah S. , Jahanyar, Jama , Shamoun, Fadi , Lee, Howard R., Solsi, Anup , Israr, Sharjeel, Mihyawi, Nawfal, Agasthi, Pradyumna , Mookadam, Farouk , Arsanjani, Reza

Mayo Clinic

The Permanente Journal | August 2, 2022 | Volume: 26 | Issue: 3 | Pages: 103-113

10.7812/tpp/21.017 | PMID 35939573 Get It

Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses
Bolivar-Wagers, Sara , Jin, Sujeong , Thangavelu, Govindarajan , Larson, Jemma H. , McDonald-Hyman, Cameron , Aguilar, Ethan G. , Saha, Asim , Koehn, Brent H. , Hefazi, Mehrdad , Osborn, Mark J. , Jensen, Michael C. , Wagner, John E. , Hefazi, Mehrdad , Koehn, Brent , Loschi, Michael L. , Pennell, Christopher A. , Blazar, Bruce R.

Mayo Clinic

JCI Insight | August 2, 2022 | Volume: 7 | Issue: 17 | Pages: No page available

10.1172/jci.insight.160674 | PMID 35917188 Get It

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) efficacy is complicated by graft-versus-host disease (GVHD), a leading cause of morbidity and mortality. Regulatory T cells (Tregs) have shown efficacy in preventing GVHD. However, high Treg doses are often required, necessitating substantial ex vivo or in vivo expansion that may diminish suppressor function. To enhance in vivo suppressor function, murine Tregs were transduced to express an anti–human CD19 chimeric antigen receptor (hCAR19) and infused into lethally irradiated, hCD19-transgenic recipients for allo-HSCT. Compared with recipients receiving control transduced Tregs, those receiving hCAR19 Tregs had a marked decrease in acute GVHD lethality. Recipient hCD19 B cells and murine hCD19 TBL12-luciferase (TBL12 luc ) lymphoma cells were both cleared by allogeneic hCAR19 Tregs, which was indicative of graft-versus-tumor (GVT) maintenance and potentiation. Mechanistically, hCAR19 Tregs killed syngeneic hCD19 + but not hCD19 – murine TBL12 luc cells in vitro in a perforin-dependent, granzyme B–independent manner. Importantly, cyclophosphamide-treated, hCD19-transgenic mice given hCAR19 cytotoxic T lymphocytes without allo-HSCT experienced rapid lethality due to systemic toxicity that has been associated with proinflammatory cytokine release; in contrast, hCAR19 Treg suppressor function enabled avoidance of this severe complication. In conclusion, hCAR19 Tregs are a potentially novel and effective strategy to suppress GVHD without loss of GVT responses.
The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All
Rosen, Allyson , AGREEDementia, members of, Arias, Jalayne J. , Ashford, J. Wesson , Blacker, Deborah , Chhatwal, Jasmeer P. , Chin, Nathan , Clark, Lindsay R. , Denny, Sharon, Gleason, Carey E. , Heidebrink, Judith L. , Henderson, Victor W. , Lavacot, James A., Lingler, Jennifer H. , Menon, Malavika, Nosheny, Rachel L. , Oliveira, Fabricio Ferreira de , Parker, Monica W. , Rahman‐Filipiak, Annalise , Revoori, Anwita, Rumbaugh, Malia, Sanchez, Danurys , Schindler, Suzanne E. , Toy, Leslie, Tyrone, Jamie, Walter, Sarah , Wang, Li-san, Zallen, Doris T. , Aggarwal, Neelum T. , AGREEDementia, members of, Chin, Nathan A., Goldman, Jill , Grill, Joshua D. , Menon, Malavika, Schwarz, Christopher G. , Wijsman, Ellen M.

Mayo Clinic

Journal of Alzheimer's Disease | August 2, 2022 | Volume: 90 | Issue: 3 | Pages: 953-962

10.3233/jad-220458 | PMID 35938255 Get It

The brain changes of Alzheimer’s disease and other degenerative dementias begin long before cognitive dysfunction develops, and in people with subtle cognitive complaints, clinicians often struggle to predict who will develop dementia. The public increasingly sees benefits to accessing dementia risk evidence (DRE) such as biomarkers, predictive algorithms, and genetic information, particularly as this information moves from research to demonstrated usefulness in guiding diagnosis and clinical management. For example, the knowledge that one has high levels of amyloid in the brain may lead one to seek amyloid reducing medications, plan for disability, or engage in health promoting behaviors to fight cognitive decline. Researchers often hesitate to share DRE data, either because they are insufficiently validated or reliable for use in individuals, or there are concerns about assuring responsible use and ensuring adequate understanding of potential problems when one’s biomarker status is known. Concerns include warning people receiving DRE about situations in which they might be compelled to disclose their risk status potentially leading to discrimination or stigma. The Advisory Group on Risk Evidence Education for Dementia (AGREEDementia) welcomes all concerned with how best to share and use DRE. Supporting understanding in clinicians, stakeholders, and people with or at risk for dementia and clearly delineating risks, benefits, and gaps in knowledge is vital. This brief overview describes elements that made this group effective as a model for other health conditions where there is interest in unfettered collaboration to discuss diagnostic uncertainty and the appropriate use and communication of health-related risk information.
Letter: The Road to the Top: How Surgical Coaching Can Enhance Performance
Singh, Rohin , Hudson, Miles , McLelland, Marissa D. , Meyer, Jenna , Vaught, Joslyn, Noland, Shelley S. , Singh, Rohin

Mayo Clinic

Neurosurgery | August 2, 2022 | Volume: 91 | Issue: 4 | Pages: e122-e123

10.1227/neu.0000000000002107 | PMID 35916595 Get It

Intravascular lithotripsy in chronic total occlusion percutaneous coronary intervention: Insights from the PROGRESS‐CTO registry
Kostantinis, Spyridon , Karácsonyi, Judit , Benton, Stewart M., Nicholson, William , Rinfret, Stéphane , Jaber, Wissam , Raj, Leah, Sandesara, Pratik B. , Basir, Mir B. , Young, Laura , Rafeh, Nidal Abi, Patel, Mitul , Kerrigan, Jimmy , Haddad, Elias V., Sandoval, Yader , Sheikh, Abdul Malik, ElGuindy, Ahmed , Göktekín, Ömer , Mastrodemos, Olga , Rangan, Bavana V. , Simsek, Bahadir , Sandesara, Pratik B , Basir, Mir B , Khatri, Jaikirshan J , Young, Laura D , Jaffer, Farouc A , Kerrigan, Jimmy L , Dattilo, Phil , Sandoval, Yader , Brilakis, Emmanouil S , Kostantinis, Spyridon , Megaly, Michael S. , Davies, Rhian E. , Alaswad, Khaldoon , Schimmel, Daniel R. , Burke, M. Nicholas , Brilakis, Emmanouil S.

Mayo Clinic

Catheterization and Cardiovascular Interventions | August 2, 2022 | Volume: 100 | Issue: 4 | Pages: 512-519

10.1002/ccd.30354 | PMID 35916076 Get It

AbstractBackgroundThe use of intravascular lithotripsy (IVL) in chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has received limited study.MethodsWe analyzed the baseline clinical and angiographic characteristics and procedural outcomes of 82 CTO PCIs that required IVL at 14 centers between 2020 and 2022.ResultsDuring the study period, IVL was used in 82 of 3301 (2.5%) CTO PCI procedures (0.4% in 2020 and 7% in 2022; p for trend < 0.001). Mean patient age was 69 ± 11 years and 79% were men. The prevalence of hypertension (95%), diabetes mellitus (62%), and prior PCI (61%) was high. The most common target vessel was the right coronary artery (54%), followed by the left circumflex (23%). The mean J‐CTO and PROGRESS‐CTO scores were 2.8 ± 1.1 and 1.3 ± 1.0, respectively. Antegrade wiring was the final successful crossing strategy in 65% and the retrograde approach was used in 22%. IVL was used in 10% of all heavily calcified lesions and 11% of all balloon undilatable lesions. The 3.5 mm lithotripsy balloon was the most commonly used balloon (28%). The mean number of pulses per lithotripsy run was 33 ± 32 and the median duration of lithotripsy was 80 (interquartile range: 40−103) seconds. Technical and procedural success was achieved in 77 (94%) and 74 (90%) cases, respectively. Two (2.4%) Ellis Class 2 perforations occurred after IVL use and were managed conservatively.ConclusionIVL is increasingly being used in CTO PCI with encouraging outcomes.
Seeking Standardized Definitions for HLA-incompatible Kidney Transplants: A Systematic Review
Jatana, Sukhdeep , Zhao, Hedi , Bow, Laurine M., Horak, Tillie, Amar‐Zifkin, Alexandre , Dadhania, Darshana M. , Cooper, Matthew , Kraus, Edward S., Sapir‐Pichhadze, Ruth , Group, on behalf of the Banff Antibody-Mediated Injury Working, Cooper, Matthew , Cozzi, Emanuele , Batal, Ibrahim , Horak, Tillie E., Schinstock, Carrie A. , Askar, Medhat , Naesens, Maarten , Group, on behalf of the Banff Antibody-Mediated Injury Working

Mayo Clinic

Transplantation | August 2, 2022 | Volume: 107 | Issue: 1 | Pages: 231-253

10.1097/tp.0000000000004262 | PMID 35915547 Get It

Background. There is no standard definition for “HLA incompatible” transplants. For the first time, we systematically assessed how HLA incompatibility was defined in contemporary peer-reviewed publications and its prognostic implication to transplant outcomes. Methods. We combined 2 independent searches of MEDLINE, EMBASE, and the Cochrane Library from 2015 to 2019. Content-expert reviewers screened for original research on outcomes of HLA-incompatible transplants (defined as allele or molecular mismatch and solid-phase or cell-based assays). We ascertained the completeness of reporting on a predefined set of variables assessing HLA incompatibility, therapies, and outcomes. Given significant heterogeneity, we conducted narrative synthesis and assessed risk of bias in studies examining the association between death-censored graft failure and HLA incompatibility. Results. Of 6656 screened articles, 163 evaluated transplant outcomes by HLA incompatibility. Most articles reported on cytotoxic/flow T-cell crossmatches (n = 98). Molecular genotypes were reported for selected loci at the allele-group level. Sixteen articles reported on epitope compatibility. Pretransplant donor-specific HLA antibodies were often considered (n = 143); yet there was heterogeneity in sample handling, assay procedure, and incomplete reporting on donor-specific HLA antibodies assignment. Induction (n = 129) and maintenance immunosuppression (n = 140) were frequently mentioned but less so rejection treatment (n = 72) and desensitization (n = 70). Studies assessing death-censored graft failure risk by HLA incompatibility were vulnerable to bias in the participant, predictor, and analysis domains. Conclusions. Optimization of transplant outcomes and personalized care depends on accurate HLA compatibility assessment. Reporting on a standard set of variables will help assess generalizability of research, allow knowledge synthesis, and facilitate international collaboration in clinical trials.
Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter Registry
Barnes, Edward L. , Deepak, Parakkal , Beniwal‐Patel, Poonam , Raffals, Laura H., Kayal, Maia , Dubinsky, Marla C. , Chang, Shannon, Higgins, Peter , Barr, Jennifer I, Galanko, Joseph A. , Jiang, Yue , Long, Millie D. , Dubinsky, Marla , Herfarth, Hans H , Kayal, Maia , Deepak, Parakkal , Jiang, Yue , Barnes, Edward L , Chang, Shannon, Cross, Raymond K. , Herfarth, Hans

Mayo Clinic

Crohn's & Colitis 360 | August 2, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1093/crocol/otac030 | PMID 36082341 Get It

Abstract Background Much of our understanding about the natural history of pouch-related disorders has been generated from selected populations. We designed a geographically diverse, prospective registry to study the disease course among patients with 1 of 4 inflammatory conditions of the pouch. The primary objectives in this study were to demonstrate the feasibility of a prospective pouch registry and to evaluate the predominant treatment patterns for pouch-related disorders. Methods We used standardized diagnostic criteria to prospectively enroll patients with acute pouchitis, chronic antibiotic-dependent pouchitis (CADP), chronic antibiotic refractory pouchitis (CARP), or Crohn’s disease (CD) of the pouch. We obtained detailed clinical and demographic data at the time of enrollment, along with patient-reported outcome (PRO) measures. Results We enrolled 318 patients (10% acute pouchitis, 27% CADP, 12% CARP, and 51% CD of the pouch). Among all patients, 55% were on a biologic or small molecule therapy. Patients with CD of the pouch were more likely to use several classes of therapy (P &lt; .001). Among patients with active disease at the time of enrollment, 23% with CARP and 40% with CD of the pouch were in clinical remission at 6 months after enrollment. Conclusions In a population where most patients had refractory inflammatory conditions of the pouch, we established a framework to evaluate PROs and clinical effectiveness. This infrastructure will be valuable for long-term studies of real-world effectiveness for pouch-related disorders.
Pharmacogenetics of Antiplatelet Therapy
Castrichini, Matteo , Luzum, Jasmine A. , Pereira, Naveen L. , Luzum, Jasmine A , Castrichini, Matteo

Mayo Clinic

Annual Review of Pharmacology and Toxicology | August 1, 2022 | Volume: 63 | Issue: 1 | Pages: 211-229

10.1146/annurev-pharmtox-051921-092701 | PMID 35914768 Get It

Antiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice. Genetic variation in CYP2C19 may influence its enzymatic activity, resulting in individuals who are carriers of loss-of-function CYP2C19 alleles and thus have reduced active clopidogrel metabolites, high on-treatment platelet reactivity, and increased ischemic risk. Prospective studies have examined the utility of CYP2C19 genetic testing to guide antiplatelet therapy, and more recently published meta-analyses suggest that pharmacogenetics represents a key treatment strategy to individualize antiplatelet therapy. Rapid genetic tests, including bedside genotyping platforms that are validated and have high reproducibility, are available to guide selection of P2Y12 inhibitors in clinical practice. The aim of this review is to provide an overview of the background and rationale for the role of a guided antiplatelet approach to enhance patient care.
A Survey of Tele-Critical Care State and Needs in 2019 and 2020 Conducted among the Members of the Society of Critical Care Medicine
Laudański, Krzysztof , Scruth, Elizabeth , Winterbottom, Fiona , Rastrepo, Mariana, Dugar, Siddharth , Herasevich, Vitaly , Villanueva, Israel, Armaignac, Donna Lee , Scott, Benjamin , Herasevich, Vitaly , Dugar, Siddharth

Mayo Clinic

Healthcare | August 1, 2022 | Volume: 10 | Issue: 8 | Pages: 1445

10.3390/healthcare10081445 | PMID 36011102 Get It

The study’s objective was to assess facilitators and barriers of Tele-Critical Care (TCC) perceived by SCCM members. By utilizing a survey distributed to SCCM members, a cross-sectional study was developed to analyze survey results from December 2019 and July 2020. SCCM members responded to the survey (n = 15,502) with a 1.9% response rate for the first distribution and a 2.54% response rate for the second survey (n = 9985). Participants (n = 286 and n = 254) were almost equally distributed between non-users, providers, users, and potential users of TCC services. The care delivery models for TCC were similar across most participants. Some consumers of TCC services preferred algorithmic coverage and scheduled rounds, while reactive and on-demand models were less utilized. The surveys revealed that outcome-driven measures were the principal form of TCC performance evaluation. A 1:100 (provider: patients) ratio was reported to be optimal. Factors related to costs, perceived lack of need for services, and workflow challenges were described by those who terminated TCC services. Barriers to implementation revolved around lack of reimbursement and adequate training. Interpersonal communication was identified as an essential TCC provider skill. The second survey introduced after the onset pandemic demonstrated more frequent use of advanced practice providers and focus on performance measures. Priorities for effective TCC deployment include communication, knowledge, optimal operationalization, and outcomes measurement at the organizational level. The potential effect of COVID-19 during the early stages of the pandemic on survey responses was limited and focused on the need to demonstrate TCC value.